Terumo (OTCMKTS:TRUMY) Sees Large Volume Increase – Still a Buy?

Terumo Corp. (OTCMKTS:TRUMY) saw strong trading volume on Thursday . 2,049,380 shares changed hands during mid-day trading, an increase of 303% from the previous session’s volume of 508,467 shares.The stock last traded at $12.73 and had previously closed at $12.67.

Terumo Trading Up 0.6%

The stock has a fifty day simple moving average of $14.04 and a 200 day simple moving average of $15.82. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.46 and a current ratio of 2.51. The firm has a market cap of $18.80 billion, a P/E ratio of 21.98 and a beta of 0.74.

Terumo (OTCMKTS:TRUMY) last announced its quarterly earnings results on Friday, February 13th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Terumo had a net margin of 11.74% and a return on equity of 9.13%. The company had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.82 billion.

Terumo Company Profile

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.